Overview

Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy tissue samples.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Oprelvekin